KOTAKBANK vs SUNPHARMA: Stock Comparison
KOTAK MAHINDRA BANK is the larger company by market capitalisation. KOTAK MAHINDRA BANK shows a lower P/E, a higher ROCE and a higher net margin, while SUN PHARMACEUTICAL IND L shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KOTAKBANK leads 5; SUNPHARMA leads 6 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| Sector | Financial Services | Healthcare |
| Industry | Private Sector Bank | Pharmaceuticals |
Price
| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| Live Price | ₹441 | ₹1,760 |
| Day Change | 1.38% | 0.01% |
| Volume | 3.15 Cr | 13.46 L |
| 52-Week High | ₹453.2 | ₹2,046.9 |
| 52-Week Low | ₹345.5 | ₹1,583.7 |
| Distance from 52W High | -2.69% | -14.02% |
Valuation
| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| Market Cap | ₹4.38 L Cr | ₹4.22 L Cr |
| P/E Ratio | 21.56x | 34.85x |
| P/B Ratio | 2.42x | 5.04x |
| EPS | ₹5.51 | ₹12.06 |
| Book Value | ₹169.27 | ₹349.6 |
| Dividend Yield | 0.15% | 0.91% |
Growth
| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -11% | 12.8% |
| EPS Growth (TTM YoY) | 9.8% | 25.6% |
| Qtr Sales Growth | — | 4.71% |
| Qtr Profit Growth | 1.58% | 7.07% |
Profitability & Leverage
Debt-to-equity is shown for reference only — it is not a like-for-like metric for banks and financials.| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| ROE | 10.36% | 11.76% |
| ROCE | 16.76% | 9.6% |
| Net Margin | 26.05% | 18.56% |
| Operating Margin | 27.66% | 22.81% |
| Debt to Equity | 0.24x | 0.6x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | KOTAKBANK | SUNPHARMA |
|---|---|---|
| Promoter Holding | 25.87% | 54.48% |
| FII Holding | 25.21%▼ 1.19 pp | 14.53%▼ 1.4 pp |
| DII Holding | 37.71%▲ 1.53 pp | 22.18%▲ 1.07 pp |
| Public Holding | 11.21%▼ 0.34 pp | 8.81%▲ 0.33 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOTAK MAHINDRA BANK and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.